The Quantellect read.As of Nov 19, 2026, 5 active firms cover Akebia Ther: 4 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $1.00 to $6.00 (about 6.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.90 sits 858% above the current $0.41. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees revenue growth near -13% this year and -23% next, consensus EPS building from about $-0.09 next quarter toward $-0.33 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy480%
Neutral120%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$3.90
+857.8% upside
Average target across 5 active firms as of Nov 19, 2026 vs $0.41 current
Highest Target$6.00
Average Target$3.90
Lowest Target$1.00
Detailed analyst forecasts for AKBA
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate AKBA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AKBA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.09
Range $-0.09 – $-0.09 · 1 analysts · +200% YoY
Next period, 1 analysts expect Akebia Ther to earn $-0.09 a share (range $-0.09 – $-0.09), versus $-0.03 a year earlier. Full-year consensus is $-0.16, growing to $-0.33 the year after.
REVENUE · NEXT QUARTER
$25.1M
Range $18.6M – $30.5M · 1 analysts · -15% YoY
Revenue is expected to reach $25.1M (range $18.6M – $30.5M), -15.0% year-over-year. Full-year consensus is $171.4M, rising to $104.6M next year.
Top analysts covering Akebia Ther
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AKBA.
#1
Roger Song
Jefferies · Rank #122
Buy
$6.00+1373.5% to target
Overall win rate
43%
+ Follow
#2
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$6.00+1373.5% to target
Overall win rate
49%
+ Follow
#3
Ed Arce
HC Wainwright & Co. · Rank #168
Buy
$7.50+1741.8% to target
Overall win rate
44%
+ Follow
#4
Julian Harrison
BTIG · Rank #183
Buy
$4.00+882.3% to target
Overall win rate
41%
+ Follow
#5
Roanna Ruiz
SVB Leerink · Rank #513
Neutral
$1.00+145.6% to target
Overall win rate
30%
+ Follow
AKBA stock forecast FAQ
What is AKBA's average 12-month price target?+
The 5 active firms with a live target average $3.90 for Akebia Ther over the next 12 months, ranging from a $6.00 high to a $1.00 low, as of Nov 19, 2026.
Is AKBA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AKBA?+
The Street-high target is $6.00 (HC Wainwright & Co.), and the Street-low is $1.00 (Leerink Partners). The average of all 5 active-firm targets is $3.90.
How many active Wall Street firms cover AKBA?+
5 active firms have a recognized rating on Akebia Ther as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AKBA?+
Among analysts who currently cover AKBA, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $6.00 target.
What is Akebia Ther's projected EPS for next quarter?+
The consensus estimate is $-0.09 per share (range $-0.09 – $-0.09) across 1 analysts. Full-year EPS is projected at $-0.16, rising to $-0.33 the following year.
How much revenue is Akebia Ther expected to report next quarter?+
Consensus revenue is $25.1M (range $18.6M – $30.5M). Full-year revenue is projected at $171.4M, growing to $104.6M next year.
Have analysts been upgrading or downgrading AKBA lately?+
As of Nov 19, 2026, 4 of 5 active firms rate AKBA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AKBA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.